Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | BCAT1 | P54687 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25275693 | 0.82 | CTSK (0.39) | ELANEAR | |
| SCHEMBL16532695 | 0.74 | MAPT (0.35) | BCAT1ELANE | |
| SCHEMBL25205878 | 0.73 | BCAT1 (0.33) | BCAT1ELANE | |
| SCHEMBL25217881 | 0.67 | RARG (0.34) | RARGRORC | |
| SCHEMBL10124297 | 0.63 | SLC34A1 (0.46) | RARGRORCAR | |
| SCHEMBL20141852 | 0.62 | GRM2 (0.45) | RORC | |
| SCHEMBL20140478 | 0.62 | ELANE (0.35) | ELANE | |
| SCHEMBL22062428 | 0.62 | CYP11B1 (0.38) | ELANE | |
| SCHEMBL30201876 | 0.61 | BCAT1 (0.66) | BCAT1ELANE | |
| SCHEMBL25278504 | 0.60 | TOP1 (0.38) | RARGRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118302411-A | Therapeutic indazole compounds and methods of use thereof for the treatment of cancer | 基因泰克公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20230202984-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230202984-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| WO-2023097195-A1 | THERAPEUTIC INDAZOLE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097195-A1 | THERAPEUTIC INDAZOLE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202984-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | RARG 457/4885RORC 240/4885BCAT1 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.